CapsoVision (CV) Competitors $4.12 +0.42 (+11.35%) As of 09/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC FilingsShort InterestTrendsBuy This Stock CV vs. BVS, AVNS, ZIMV, KIDS, TMCI, CBLL, SMLR, DCTH, BFLY, and RXSTShould you be buying CapsoVision stock or one of its competitors? The main competitors of CapsoVision include Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), CeriBell (CBLL), Semler Scientific (SMLR), Delcath Systems (DCTH), Butterfly Network (BFLY), and RxSight (RXST). These companies are all part of the "medical equipment" industry. CapsoVision vs. Its Competitors Bioventus Avanos Medical ZimVie OrthoPediatrics Treace Medical Concepts CeriBell Semler Scientific Delcath Systems Butterfly Network RxSight CapsoVision (NASDAQ:CV) and Bioventus (NYSE:BVS) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Which has stronger valuation & earnings, CV or BVS? CapsoVision has higher earnings, but lower revenue than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapsoVision$12.52M15.40N/AN/AN/ABioventus$564.14M1.06-$156.23MN/AN/A Do analysts prefer CV or BVS? CapsoVision currently has a consensus target price of $5.50, indicating a potential upside of 33.50%. Bioventus has a consensus target price of $13.75, indicating a potential upside of 90.18%. Given Bioventus' higher probable upside, analysts clearly believe Bioventus is more favorable than CapsoVision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CapsoVision 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders & institutionals believe in CV or BVS? 62.9% of Bioventus shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is CV or BVS more profitable? CapsoVision has a net margin of 0.00% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat CapsoVision's return on equity.Company Net Margins Return on Equity Return on Assets CapsoVisionN/A N/A N/A Bioventus -7.11%15.61%4.01% Does the media favor CV or BVS? In the previous week, CapsoVision had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for CapsoVision and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.74 beat CapsoVision's score of 1.47 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryBioventus beats CapsoVision on 8 of the 13 factors compared between the two stocks. Get CapsoVision News Delivered to You Automatically Sign up to receive the latest news and ratings for CV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CV vs. The Competition Export to ExcelMetricCapsoVisionSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$173.06M$199.29M$2.57B$10.14BDividend YieldN/AN/A2.52%4.60%P/E RatioN/A2.0826.5525.98Price / Sales15.4020.35106.93181.19Price / CashN/A4.1049.2160.44Price / BookN/A1.6134.656.29Net IncomeN/A-$66.04M$16.40M$271.07M7 Day Performance15.08%3.74%1.86%3.87%1 Month Performance1.23%-5.29%3.68%4.88%1 Year PerformanceN/A133.74%35.85%26.12% CapsoVision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVCapsoVisionN/A$4.12+11.4%$5.50+33.5%N/A$173.06M$12.52M0.0090News CoveragePositive NewsGap DownBVSBioventus3.3173 of 5 stars$7.19+1.3%$13.75+91.2%-33.7%$594.46M$564.14M-11.791,200Positive NewsAVNSAvanos Medical2.1563 of 5 stars$12.70+0.3%N/A-48.0%$590.23M$687.80M-1.262,227Positive NewsZIMVZimVie1.2699 of 5 stars$18.85-0.2%$17.75-5.8%+16.2%$531.78M$449.75M-26.931,770News CoveragePositive NewsKIDSOrthoPediatrics4.3448 of 5 stars$20.91+1.0%$34.14+63.3%-37.8%$524.30M$204.73M-11.68200News CoverageTMCITreace Medical Concepts2.3819 of 5 stars$7.17flat$9.83+37.1%+42.7%$452.95M$209.36M-9.08250CBLLCeriBell2.6774 of 5 stars$11.80-4.3%$32.14+172.4%N/A$432.64M$65.44M-3.95N/APositive NewsSMLRSemler Scientific2.9958 of 5 stars$28.12+0.1%$81.75+190.7%+18.7%$416.32M$42.98M11.57120News CoverageDCTHDelcath Systems3.0617 of 5 stars$11.65+5.0%$24.50+110.3%+10.5%$407.53M$70.24M233.0060Positive NewsBFLYButterfly Network3.1678 of 5 stars$1.56+1.6%$3.00+92.9%-17.6%$392.72M$82.06M-5.55460RXSTRxSight1.862 of 5 stars$8.89+5.0%$10.00+12.5%-82.9%$363.74M$139.93M-11.11220Trending News Related Companies and Tools Related Companies BVS Alternatives AVNS Alternatives ZIMV Alternatives KIDS Alternatives TMCI Alternatives CBLL Alternatives SMLR Alternatives DCTH Alternatives BFLY Alternatives RXST Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CV) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CapsoVision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CapsoVision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CV Stock Alerts